GO:0044754 autolysosome: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044754 autolysosome is a secondary lysosome formed when a primary lysosome fuses with an autophagosome or amphisome, degrading autophagic cargo with acidic hydrolases.
• Autolysosome formation is the terminal step of autophagy and requires autophagosome maturation, SNARE-mediated fusion, and lysosomal acidification.
• Faulty autolysosome acidification causes autophagic build-up of amyloid-beta in neurons and contributes to senile plaque formation in Alzheimer's disease models.
• Autolysosome dysfunction is linked to obesity-induced metabolic inflammation, cardiotoxicity, and impaired extracellular matrix turnover.
• Key molecular players include DRAM1, VAMP8, TFEB, UCHL3, and TFAM, which regulate autolysosome formation, stability, and cargo handling.
• CRISPR knockout, knock-in, and overexpression models are essential to dissect causal roles of autolysosome genes in disease.
Description
The autolysosome (GO:0044754) is a cellular component defined as a secondary lysosome formed by fusion of a primary lysosome with the outer membrane of an autophagosome or amphisome. This organelle executes the second step of autophagy, in which acidic lysosomal hydrolases degrade autophagic contents. Because it sits at the intersection of autophagy, lysosomal biology, and cellular stress responses, the autolysosome is a focal point for understanding how cells recycle damaged organelles and proteins. Researchers study autolysosomes to uncover mechanisms of neurodegeneration, metabolic disease, and cancer, where impaired autolysosomal degradation leads to toxic accumulation of substrates. For example, in Alzheimer's disease models, faulty autolysosome acidification causes autophagic build-up of amyloid-beta in neurons, yielding senile plaques. In obesity, autolysosomal dysfunction drives metabolic inflammation and related disorders. Thus, GO:0044754 represents a critical node for therapeutic intervention and biomarker discovery.
autolysosome At A Glance
| GO ID | GO:0044754 |
|---|---|
| GO term | autolysosome |
| Ontology | cellular_component |
| Synonym | AVd, degrading autophagic vacuole |
| Major function | Degradation of autophagic cargo using acidic lysosomal hydrolases |
| Parent structure | Secondary lysosome |
| Formation | Fusion of primary lysosome with autophagosome or amphisome |
| Pathophysiological relevance | Alzheimer's disease, obesity-induced metabolic inflammation, cardiotoxicity |
What Is GO:0044754?
According to the Gene Ontology, GO:0044754 autolysosome is a type of secondary lysosome in which a primary lysosome has fused with the outer membrane of an autophagosome or amphisome. It is involved in the second step of autophagy in which it degrades contents with acidic lysosomal hydrolases. Synonyms include AVd and degrading autophagic vacuole.
Why Is autolysosome Important in Cell Biology?
The autolysosome is essential for cellular homeostasis because it completes the autophagic degradation of cytoplasmic material, including damaged organelles, protein aggregates, and pathogens. Defects in autolysosome formation or acidification lead to accumulation of toxic substrates, as seen in Alzheimer's disease where autophagic build-up of amyloid-beta contributes to senile plaques. Autolysosome dysfunction also promotes metabolic inflammation in obesity and mediates doxorubicin-induced cardiotoxicity. Understanding autolysosome biology therefore offers therapeutic opportunities for neurodegeneration, metabolic disorders, and cancer.
• Central to autophagy completion and cellular quality control.
• Implicated in Alzheimer's disease via faulty acidification and amyloid-beta accumulation.
• Linked to obesity-induced metabolic inflammation and related disorders.
• Mediates doxorubicin-induced cardiotoxicity through impaired degradation.
• Required for extracellular matrix remodeling and cell migration via DRAM1-VAMP8 axis.
• Limits inflammation by degrading cytoplasmic mitochondrial DNA through TFAM.
• Protects against lysosome damage via migratory autolysosome disposal.
• Target for therapeutic modulation in neurodegeneration and metabolic disease.
Structure and Composition of autolysosome
Formation by membrane fusion
In simple terms: The autolysosome is made when a lysosome merges with an autophagosome.
Autolysosome formation requires the fusion of a primary lysosome with the outer membrane of an autophagosome or amphisome. This process is mediated by SNARE proteins, including VAMP8, whose stability is promoted by DRAM1 to enhance autolysosome formation. The resulting organelle is a secondary lysosome specialized for degradation.
Acidification and hydrolase content
In simple terms: The autolysosome becomes acidic to activate digestive enzymes.
Autolysosomes degrade contents with acidic lysosomal hydrolases. Proper acidification is critical; in Alzheimer's disease models, faulty autolysosome acidification impairs degradation and causes autophagic build-up of amyloid-beta. The acidic environment is maintained by lysosomal proton pumps and ion channels.
Membrane protein composition
In simple terms: Specific proteins on the autolysosome surface control its function.
Key membrane proteins include VAMP8, which mediates fusion, and DRAM1, which stabilizes VAMP8. TFEB regulates lysosomal biogenesis and autolysosome function through the UCHL3-TFEB pathway. TFAM acts as an autophagy receptor that binds cytoplasmic mitochondrial DNA to limit inflammation.
Dynamic regulation and disposal
In simple terms: Autolysosomes can move and be disposed of to protect cells.
Migratory autolysosome disposal mitigates lysosome damage by transporting damaged organelles for clearance. This dynamic regulation ensures cellular protection under stress. Autolysosome maturation is tightly controlled by signaling pathways including mTOR.
Key Genes Involved in GO:0044754 autolysosome
The following genes and proteins are experimentally implicated in autolysosome biology, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DRAM1 | Promotes stability of lysosomal VAMP8 to enhance autolysosome formation | Facilitates extravasation and extracellular matrix turnover |
| VAMP8 | SNARE protein mediating autolysosome fusion | Target for enhancing autolysosome formation |
| TFEB | Transcription factor regulating lysosomal biogenesis and autolysosome function | Modulated by UCHL3 in cardiotoxicity |
| UCHL3 | Deubiquitinase regulating TFEB pathway | Promotes autolysosome degradation in doxorubicin cardiotoxicity |
| TFAM | Autophagy receptor binding cytoplasmic mitochondrial DNA | Limits inflammation by degrading mtDNA |
| MAP1LC3B | Autophagosome membrane protein, substrate for autolysosomal degradation | Marker of autophagic flux |
| SQSTM1 | Autophagy receptor degraded in autolysosomes | Indicator of autolysosomal degradation efficiency |
| LAMP1 | Lysosomal membrane protein | Marker for autolysosome identification |
| LAMP2 | Lysosomal membrane protein | Marker for autolysosome identification |
| ATP6V1A | V-ATPase subunit for lysosomal acidification | Required for autolysosome acidification |
| CTSB | Lysosomal protease | Degrades autophagic cargo |
| CTSD | Lysosomal protease | Degrades autophagic cargo |
| RAB7A | Late endosome/lysosome GTPase | Regulates autolysosome fusion |
| STX17 | Autophagosomal SNARE | Mediates autophagosome-lysosome fusion |
| SNAP29 | SNARE protein | Mediates autophagosome-lysosome fusion |
| VTI1B | SNARE protein | Mediates autolysosome formation |
| BECN1 | Autophagy initiation | Upstream regulator of autolysosome formation |
| MTOR | Kinase inhibiting autophagy | Regulates autolysosome formation via autophagy initiation |
How Is autolysosome Regulated?
Autolysosome formation and function are regulated by multiple signaling pathways. mTOR kinase inhibits autophagy initiation, thereby limiting autolysosome formation. TFEB controls lysosomal biogenesis and autolysosome function, and its activity is modulated by UCHL3. DRAM1 stabilizes VAMP8 to enhance autolysosome formation. Acidification is regulated by V-ATPase and ion channels, and defects in this process are linked to Alzheimer's disease. Migratory disposal of autolysosomes provides a protective mechanism against lysosome damage.
autolysosome and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DRAM1 | Cancer metastasis and extravasation | Knockout and overexpression in cancer cell lines |
| TFEB | Doxorubicin-induced cardiotoxicity | Cardiomyocyte-specific knockout |
| UCHL3 | Cardiotoxicity | Knockout and point mutation models |
| TFAM | Inflammation and mtDNA-driven immune responses | Knockout macrophages |
| VAMP8 | Autolysosome formation and extracellular matrix remodeling | Knockout and knock-in models |
Alzheimer's disease
Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of amyloid-beta in neurons, yielding senile plaques. Endolysosome and autolysosome dysfunction in Alzheimer's disease represents a point where intracellular and extracellular pathology meet. These findings suggest that restoring autolysosome function could be therapeutic.
Obesity-induced metabolic inflammation
Autolysosomal dysfunction in obesity-induced metabolic inflammation and related disorders contributes to disease pathogenesis. Impaired autolysosomal degradation leads to accumulation of inflammatory triggers. Targeting autolysosome function may mitigate metabolic inflammation.
Cardiotoxicity
20-Deoxyingenol attenuated doxorubicin-induced cardiotoxicity by promoting autolysosome degradation through the UCHL3-TFEB pathway. This highlights autolysosome modulation as a cardioprotective strategy.
Cancer and metastasis
DRAM1 promotes autolysosome formation and facilitates extravasation, a critical step in metastasis. Migratory autolysosome disposal mitigates lysosome damage, supporting cancer cell survival. Autolysosome components are potential targets in cancer therapy.
From autolysosome-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DRAM1 impair autolysosome formation? | DRAM1 knockout cell lines |
| Does TFEB phosphorylation regulate autolysosome function? | TFEB point mutation knock-in |
| How does VAMP8 stabilization affect autolysosome fusion? | VAMP8 tagged knock-in |
| Does TFAM act as an autophagy receptor for mtDNA? | TFAM knockout and overexpression |
| Can enhancing autolysosome degradation protect against cardiotoxicity? | UCHL3 overexpression in cardiomyocytes |
| Does migratory autolysosome disposal require specific motor proteins? | Knockout of candidate motors |
How to Study the autolysosome Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Fluorescence microscopy | Autolysosome number, size, and acidification | Visualizing autolysosome formation |
| Western blot | LC3-II and SQSTM1 levels | Measuring autophagic flux |
| Electron microscopy | Ultrastructure of autolysosomes | Confirming fusion events |
| CRISPR knockout screens | Genes required for autolysosome function | Identifying novel regulators |
| Proteomics | Protein composition of autolysosomes | Discovering new components |
| Live-cell imaging | Migratory autolysosome disposal | Tracking organelle movement |
| pH-sensitive dyes | Lysosomal acidification | Assessing acidification defects |
| Bioinformatics | Gene expression signatures | Linking autolysosome genes to disease |
Imaging autolysosomes
Fluorescence microscopy with markers such as LAMP1 and LC3 can visualize autolysosome formation and acidification. Live-cell imaging tracks migratory autolysosome disposal. Electron microscopy provides ultrastructural evidence of autolysosome fusion.
Biochemical assays
Western blotting for LC3-II and SQSTM1 measures autophagic flux and autolysosomal degradation. Lysosomal acidification can be assessed with pH-sensitive dyes. Protease activity assays measure hydrolase function.
Genetic screens
CRISPR knockout screens identify genes required for autolysosome formation and function. Overexpression screens reveal enhancers of autolysosomal degradation. Bioinformatics analysis of transcriptomic data links autolysosome genes to disease.
Proteomics and interactomics
Mass spectrometry identifies autolysosome protein composition and post-translational modifications. Proximity labeling maps interactions between SNAREs and regulators. Phosphoproteomics reveals signaling events controlling autolysosome function.
How CRISPR Can Be Used to Study GO:0044754 autolysosome
Knockout
CRISPR knockout of autolysosome genes such as DRAM1, VAMP8, or TFEB allows researchers to test their requirement for autolysosome formation and degradation. Knockout models reveal accumulation of autophagic substrates and cellular phenotypes.
Point Mutation
Point mutation knock-in can mimic disease-associated variants or phospho-null/phospho-mimetic mutations in genes like TFEB to dissect regulatory mechanisms. These models provide precise insights into autolysosome regulation.
Knock-in
Tagged knock-in of endogenous genes such as LAMP1 or VAMP8 enables real-time tracking of autolysosomes and their fusion dynamics. Knock-in reporters facilitate high-content screening.
Overexpression
Overexpression of DRAM1 or UCHL3 enhances autolysosome formation and degradation, providing gain-of-function models to test therapeutic potential. Overexpression in disease models can rescue phenotypes.
How EDITGENE Supports autolysosome Research
Researchers studying autolysosome-related genes often need to determine whether a candidate gene is causally involved in autolysosome formation, acidification, or degradation. EDITGENE provides CRISPR-based cell models and screening services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for autolysosome research.
Frequently Asked Questions About autolysosome
What is an autolysosome?
An autolysosome (GO:0044754) is a secondary lysosome formed when a primary lysosome fuses with an autophagosome or amphisome, degrading contents with acidic hydrolases.
What genes are involved in autolysosome formation?
Key genes include DRAM1, VAMP8, TFEB, UCHL3, and TFAM, which regulate fusion, acidification, and cargo degradation.
How is autolysosome dysfunction linked to Alzheimer's disease?
Faulty autolysosome acidification causes autophagic build-up of amyloid-beta in neurons, leading to senile plaques.
What is the role of DRAM1 in autolysosomes?
DRAM1 promotes the stability of lysosomal VAMP8 to enhance autolysosome formation and facilitates extravasation.
How does TFEB regulate autolysosomes?
TFEB controls lysosomal biogenesis and autolysosome function, and its activity is modulated by UCHL3.
What methods are used to study autolysosomes?
Common methods include fluorescence microscopy, Western blot for LC3-II, electron microscopy, and CRISPR screens.
What is the difference between autophagosome and autolysosome?
An autophagosome is a double-membrane vesicle that fuses with a lysosome to form an autolysosome, where degradation occurs.
Can autolysosome function be targeted therapeutically?
Yes, enhancing autolysosome degradation has shown protective effects in cardiotoxicity and may benefit neurodegeneration.
What is the role of TFAM in autolysosomes?
TFAM acts as an autophagy receptor that binds cytoplasmic mitochondrial DNA to limit inflammation.
How does obesity affect autolysosomes?
Obesity-induced metabolic inflammation is associated with autolysosomal dysfunction and related disorders.
Conclusion
The autolysosome (GO:0044754) is a critical cellular component for completing autophagy and maintaining cellular homeostasis. Its dysfunction is implicated in Alzheimer's disease, metabolic inflammation, and cardiotoxicity, making it a promising therapeutic target. Advances in CRISPR modeling and imaging continue to unravel the molecular mechanisms governing autolysosome formation and function.
References
- 1. Lee JH et al.. 2022. Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of Aβ in neurons, yielding senile plaques.. Nat Neurosci 25(6):688-701 PMID: 35654956
- 2. van Weering JRT et al.. 2019. Endolysosome and Autolysosome Dysfunction in Alzheimer's Disease: Where Intracellular and Extracellular Meet.. CNS Drugs 33(7):639-648 PMID: 31165364
- 3. Zhang R et al.. 2025. DRAM1 promotes the stability of lysosomal VAMP8 to enhance autolysosome formation and facilitates the extravasation.. Nat Commun 16(1):5826 PMID: 40595569
- 4. Liu H et al.. 2024. TFAM is an autophagy receptor that limits inflammation by binding to cytoplasmic mitochondrial DNA.. Nat Cell Biol 26(6):878-891 PMID: 38783142
- 5. Sho T et al.. 2024. Migratory autolysosome disposal mitigates lysosome damage.. J Cell Biol 223(12) PMID: 39347717
- 6. Zhao YG et al.. 2021. Machinery, regulation and pathophysiological implications of autophagosome maturation.. Nat Rev Mol Cell Biol 22(11):733-750 PMID: 34302147
- 7. Chen DS et al.. 2025. 20-Deoxyingenol attenuated doxorubicin-induced cardiotoxicity by promoting autolysosome degradation through the UCHL3-TFEB pathway.. Phytomedicine 147:157220 PMID: 40916238
- 8. Cheong LYT et al.. 2025. Autolysosomal Dysfunction in Obesity-induced Metabolic Inflammation and Related Disorders.. Curr Obes Rep 14(1):43 PMID: 40366502
